MX2022012942A - Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina. - Google Patents

Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina.

Info

Publication number
MX2022012942A
MX2022012942A MX2022012942A MX2022012942A MX2022012942A MX 2022012942 A MX2022012942 A MX 2022012942A MX 2022012942 A MX2022012942 A MX 2022012942A MX 2022012942 A MX2022012942 A MX 2022012942A MX 2022012942 A MX2022012942 A MX 2022012942A
Authority
MX
Mexico
Prior art keywords
alvelestat
alpha
respiratory disease
methods involving
neutrophil elastase
Prior art date
Application number
MX2022012942A
Other languages
English (en)
Spanish (es)
Inventor
Jacqueline Parkin
Original Assignee
Mereo Biopharma 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=78083570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022012942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2005520.8A external-priority patent/GB202005520D0/en
Priority claimed from GBGB2005519.0A external-priority patent/GB202005519D0/en
Application filed by Mereo Biopharma 4 Ltd filed Critical Mereo Biopharma 4 Ltd
Publication of MX2022012942A publication Critical patent/MX2022012942A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2022012942A 2020-04-16 2021-03-16 Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina. MX2022012942A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2005520.8A GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
GBGB2005519.0A GB202005519D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
US202062706195P 2020-08-04 2020-08-04
PCT/GB2021/050653 WO2021209739A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
MX2022012942A true MX2022012942A (es) 2023-01-11

Family

ID=78083570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012942A MX2022012942A (es) 2020-04-16 2021-03-16 Metodos que involucran el inhibidor de la elastasa de neutrofilo alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina.

Country Status (16)

Country Link
US (2) US20230218596A1 (enExample)
EP (2) EP4252850A3 (enExample)
JP (1) JP2023522010A (enExample)
AU (1) AU2021256835A1 (enExample)
DK (1) DK4106757T3 (enExample)
ES (1) ES2962498T3 (enExample)
FI (1) FI4106757T3 (enExample)
HR (1) HRP20231065T1 (enExample)
HU (1) HUE064089T2 (enExample)
IL (1) IL297211B2 (enExample)
LT (1) LT4106757T (enExample)
MX (1) MX2022012942A (enExample)
PL (1) PL4106757T3 (enExample)
PT (1) PT4106757T (enExample)
SI (1) SI4106757T1 (enExample)
WO (2) WO2021209740A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4138906A4 (en) * 2020-04-20 2024-10-30 Tran, Lloyd Hung Loi METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19
US20230285523A1 (en) * 2021-12-20 2023-09-14 Tiakis Biotech Ag Use of elafin in the treatment of covid-19
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
WO2025056602A1 (en) * 2023-09-11 2025-03-20 Elastin Biosciences Ltd. Pharmaceutical compositions and use thereof in treatment of conditions and diseases related to elastin deficiency and/or aging
IL327315A (en) 2023-10-11 2026-05-01 Mereo Biopharma 4 Ltd Elovastat and alpha-1 antitrypsin for the treatment of respiratory disorders
IL327395A (en) 2023-12-21 2026-05-01 Mereo Biopharma 4 Ltd Use of ALVELESTAT in specific patients
GB202319953D0 (en) 2023-12-22 2024-02-07 Mereo Biopharma 4 Ltd Tablet formulations involving alvelestat
KR20250172196A (ko) * 2024-05-31 2025-12-09 고려대학교 산학협력단 폐 계면활성제 및 항섬유화제를 포함하는 폐섬유증의 예방 또는 치료용 조성물 및 이의 제조방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015605A2 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
ATE181925T1 (de) 1991-05-23 1999-07-15 Merrell Pharma Inc Hemmstoffe für kathepsin-g und elastase zur verhütung von bindegewebsabbau
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
JPH07505877A (ja) 1992-04-16 1995-06-29 ゼネカ・リミテッド α−アミノボロン酸ペプチド及びエラスターゼ阻害剤としてのそれらの使用
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
JPH07505875A (ja) 1992-04-16 1995-06-29 ゼネカ・リミテッド α−アミノボロン酸ペプチドおよびエラスターゼ阻害物質としてのそれらの用途
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
HU221197B1 (en) 1994-06-02 2002-08-28 Aventis Pharma Inc Elastase inhibitor tripeptides and pharmaceutical compositions comprising thereof
DK0763055T3 (da) 1994-06-02 2000-05-08 Merrell Pharma Inc Perflouralkylketon-inhibitorer af elastase og fremgangsmåde til fremstilling deraf
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
EA001437B1 (ru) 1996-03-28 2001-02-26 Глаксо Груп Лимитед Производные пирролопирролона в качестве ингибиторов нейтрофильной эластазы
US6103498A (en) 1996-04-12 2000-08-15 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
KR20010078725A (ko) 1998-06-03 2001-08-21 존 더블류. 갈루치 2세 세린 프로테아제 저해제로서의 펩토이드 및 비펩토이드를함유하는 알파-케토 옥사디아졸
JP2004517028A (ja) 1998-06-03 2004-06-10 コーテック インコーポレーテッド セリンプロテアーゼ阻害剤としてのα−ケトオキサジアゾール類含有インドールおよびテトラヒドロイソキノリン
US20030069187A1 (en) 2001-10-05 2003-04-10 Rao Srinivasa K. Elastase inhibitors
US20030119073A1 (en) 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
WO2005082864A1 (en) 2004-02-26 2005-09-09 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
ES2428503T3 (es) 2004-02-26 2013-11-08 Bayer Intellectual Property Gmbh 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
WO2006070012A1 (en) 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
NZ572250A (en) 2006-05-04 2011-10-28 Pulmagen Therapeutics Inflammation Ltd Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
RU2419625C2 (ru) 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2293832B1 (es) 2006-07-17 2009-05-04 Cargoflet S.A. Sistema de transporte masivo de gas natural a alta presion por via maritima.
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
CN101535304A (zh) 2006-09-21 2009-09-16 埃迪威克斯生物科学公司 丝氨酸水解酶抑制剂
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
KR20090108131A (ko) 2007-02-09 2009-10-14 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CA2703996A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
GB0817429D0 (en) 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
RU2012116877A (ru) 2009-10-02 2013-11-10 Астразенека Аб Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
US20110212181A1 (en) 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
TWI568735B (zh) 2011-09-14 2017-02-01 吉斯藥品公司 新穎化合物
WO2013084199A1 (en) 2011-12-07 2013-06-13 Universidade De Lisboa Boron heterocycles as new inhibitors of human neutrophil elastase
RU2638537C2 (ru) 2012-07-12 2017-12-14 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибирование ферментов
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
RU2016123379A (ru) 2013-12-16 2017-12-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека
EA034910B1 (ru) 2013-12-27 2020-04-06 Полифор Аг Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
NZ722025A (en) 2013-12-27 2019-06-28 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015200349A2 (en) * 2014-06-24 2015-12-30 The California Institute For Biomedical Research Elastase inhibitors
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016020070A1 (en) 2014-08-05 2016-02-11 Gerard Voerman Mutants of leech derived neutrophil elastase inhibitors and uses thereof
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
AR106958A1 (es) 2015-12-14 2018-03-07 Chiesi Farm Spa Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne
EA036456B1 (ru) 2016-05-31 2020-11-12 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Имидазолиновые соединения в качестве ингибиторов эластазы нейтрофилов человека
CA3054267A1 (en) * 2017-02-21 2018-08-30 Kamada Ltd. Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases
WO2021053058A1 (en) * 2019-09-17 2021-03-25 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity

Also Published As

Publication number Publication date
US20230190723A1 (en) 2023-06-22
SI4106757T1 (sl) 2023-11-30
AU2021256835A1 (en) 2022-10-13
LT4106757T (lt) 2023-11-10
HRP20231065T1 (hr) 2023-12-22
PL4106757T3 (pl) 2024-01-22
EP4252850A2 (en) 2023-10-04
US20230218596A1 (en) 2023-07-13
PT4106757T (pt) 2023-11-17
WO2021209739A1 (en) 2021-10-21
IL297211B2 (en) 2025-12-01
IL297211A (en) 2022-12-01
HUE064089T2 (hu) 2024-02-28
EP4106757A1 (en) 2022-12-28
ES2962498T3 (es) 2024-03-19
IL297211B1 (en) 2025-08-01
WO2021209740A1 (en) 2021-10-21
JP2023522010A (ja) 2023-05-26
EP4252850A3 (en) 2023-11-15
FI4106757T3 (fi) 2023-10-23
DK4106757T3 (da) 2023-10-23
EP4106757B1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
EP4252850A3 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
JP2021119196A5 (enExample)
ECSP19015828A (es) Composiciones para comprimidos
ZA202310378B (en) Complement factor b inhibitor, and pharmaceutical composition thereof, preparation method therefor and use thereof
ATE498620T1 (de) 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs
JP2004534010A5 (enExample)
CY1112021T1 (el) Αναστολεις της προλυλ υδροξυλασης και μεθοδοι χρησης
CY1111772T1 (el) Μονοϋδροχλωρικο μονοϋδρικο αλας 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλο)-5-τριφλουορομεθυλο-φαινυλο]-3-(4-πυριδιν-3-υλο-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
NO20072344L (no) Trombineresptorantagonister.
PE20190472A1 (es) Inhibidores de bromodominios
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
MX2011008389A (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, util en el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
NZ600400A (en) Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
AR064302A1 (es) Arilpirazoles sustitudos
AR120799A1 (es) 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
NZ598394A (en) Indenone derivative and pharmaceutical composition comprising same
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
AR118038A1 (es) Composición herbicida y método para controlar malezas
IN2014DN03416A (enExample)
PE20050357A1 (es) Composicion que comprende 5-[4-[2-(n-metil-n-(2-piridil)-amino)-etoxi]-bencil]-tiazolidino-2,4-diona
DK1587584T3 (da) Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme
DK3801515T3 (da) 5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme
JP2013522350A5 (enExample)